The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on the ...
Boston Scientific (NYSE:BSX) announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX ...
The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...
Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...
Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).
Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...
Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.
Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...
Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...
Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...